EUVIMEDEUVIMED entdecken
Open Access

TITE-safety: a robust time-to-event safety monitoring approach for clinical trials

Michael J Martens iD, Qinghua Lian, Brent R Logan iD

Biometrics · 09.04.2026 · 82 (2)

DOI: 10.1093/biomtc/ujag097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, online erschienen am 27.05.2026. Verfasst von Michael J Martens und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 53226, United States. Hauptthemen laut MEDLINE: Clinical Trials as Topic. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Center on Minority Health and Health Disparities, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Safety evaluation is an essential component of clinical trials. To protect study participants, these studies often implement safety stopping rules that will halt the trial if an excessive number of toxicity events occur. Existing safety monitoring methods usually treat these events as binary outcomes. A strategy that instead handles these as time-to-event (TITE) endpoints can offer higher power and a reduced time to signal of excess risk, but must manage additional complexities including censoring and competing risks. We propose the TITE-safety approach for safety monitoring, which incorporates TITE information while handling repeated analyses, censored observations, and competing risks appropriately. This strategy is applied to develop stopping rules using score tests, Bayesian beta-extended binomial models, and sequential probability ratio tests. Operating characteristics of these methods are studied via simulation for common phase 2 and 3 trial scenarios. Across simulation settings, the proposed techniques offer reductions in expected toxicities of 20% or more compared to binary data methods and maintain the type I error rate near the nominal level for various event time distributions. These methods are demonstrated through a redesign of the safety monitoring scheme for Blood and Marrow Transplant Clinical Trials Network 0601, a single arm, phase 2 trial that evaluated bone marrow transplant as treatment for sickle cell disease. Our R package “stoppingrule” offers functions to construct and evaluate these stopping rules, providing valuable tools for trial design to investigators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicHumansComputer SimulationBayes TheoremAnemia, Sickle CellModels, StatisticalEndpoint DeterminationBone Marrow Transplantation

Stichwörter der Autor:innen

R software packagecompeting riskssafety monitoringsequential testingsickle cell diseasetime-to-event analysis

Autor:innen und Institutionen

  • Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
  • Center for International Blood and Marrow Transplant Research, Milwaukee, WI 53226, United States.
  • Bristol Myers Squibb, Lawrenceville, NJ 08648, United States.

ORCID-Profile: Michael J Martens, Brent R Logan

Förderung

  • NCI NIH HHS
  • National Center on Minority Health and Health Disparities
  • National Cancer Institute

Zitieren

APA

Martens, M. J., Lian, Q., & Logan, B. R. (2026). TITE-safety: a robust time-to-event safety monitoring approach for clinical trials. Biometrics, 82(2). https://doi.org/10.1093/biomtc/ujag097

Vancouver

Martens MJ, Lian Q, Logan BR. TITE-safety: a robust time-to-event safety monitoring approach for clinical trials. Biometrics. 2026;82(2). doi:10.1093/biomtc/ujag097

BibTeX
@article{Martens2026,
  author = {Martens, Michael J and Lian, Qinghua and Logan, Brent R},
  title = {TITE-safety: a robust time-to-event safety monitoring approach for clinical trials},
  journal = {Biometrics},
  year = {2026},
  volume = {82},
  number = {2},
  doi = {10.1093/biomtc/ujag097}
}
Kostenlos starten →